Law
Offices of Howard G. Smith announces that it is investigating
potential claims on behalf of investors Ampio Pharmaceuticals, Inc.
(“Ampio” or the “Company”) (AMEX:AMPE) concerning the Company’s and its
officers’ possible violations of federal securities laws.
The investigation focuses on whether the Company and its executives
violated federal securities laws by failing to disclose that (1) the
clinical research organization conducting the STEP Study lacked
autonomy; and (2) the trial drug supply for the STEP Study was shipped
to clinical sites at lower temperatures than were permitted by the
drug’s specifications. As a result of the Company’s fraudulent conduct
investors have been severely damaged. On April 20, 2015, Ampio announced
that, “the multiple injection STRIDE study AP008 did not reach its
primary endpoint against the saline control test.” On this news, shares
of Ampio fell $5.18 per share, to close at $2.69, or more than 65.8%, on
April 24, 2015.
If you purchased shares of Ampio prior to August 21, 2014, have
information or would like to learn more about these claims, or have any
questions concerning this announcement or your rights or interests with
respect to these matters, please contact Howard G. Smith, Esquire, of
Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem,
Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888)
638-4847, or by email to howardsmith@howardsmithlaw.com,
or visit our website at http://www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150605006024/en/
Copyright Business Wire 2015